Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): Study protocol for a randomized controlled trial

Trials

Volumn 12, Issue , 2011, Pages

  Chrispijn, Melissa ^a   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; LONG ACTING DRUG; OCTREOTIDE; DRUG DERIVATIVE; RAPAMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; MALE; MONOTHERAPY; OPEN STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; AGED; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYST; DRUG COMBINATION; LIVER DISEASE; MIDDLE AGED; SAMPLE SIZE;

ADULT; AGED; CLINICAL PROTOCOLS; CYSTS; DRUG THERAPY, COMBINATION; HUMANS; LIVER DISEASES; MIDDLE AGED; OCTREOTIDE; SAMPLE SIZE; SIROLIMUS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 81355138165     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-246     Document Type: Article

References (21)

1. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. Hepatology 2010, 52:2223-2230. 10.1002/hep.24036, 21105111.
2. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006, 1:64-69.
3. van Keimpema L, de Koning DB, van Hoek B, van den Berg AP, van Oijen MG, de Man RA, et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int 2011, 31:92-98. 10.1111/j.1478-3231.2010.02247.x, 20408955.
4. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 2007, 132:1104-1116. 10.1053/j.gastro.2006.12.039, 17383431.
5. van Keimpema L, de Man RA, Drenth JP. Somatostatin analogues reduce liver volume in polycystic liver disease. Gut 2008, 57:1338-1339. 10.1136/gut.2008.155721, 18719151.
6. van Keimpema L, Drenth JP. Effect of octreotide on polycystic liver volume. Liver Int 2010, 30:633-634. 10.1111/j.1478-3231.2009.02123.x, 19744163.
7. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009, 137:1661-1668. 10.1053/j.gastro.2009.07.052, 19646443.
8. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010, 21:1052-1061. 10.1681/ASN.2009121291, 2900957, 20431041.
9. Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010, 5:783-789. 10.2215/CJN.05380709, 2863977, 20185596.
10. Qian Q, Du H, King BF, Kumar S, Dean PG, Cosio FG, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008, 19:631-638. 10.1681/ASN.2007050626, 2391057, 18199797.
11. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006, 103:5466-5471. 10.1073/pnas.0509694103, 1459378, 16567633.
12. Wahl PR, Serra AL, Le HM, Molle KD, Hall MN, Wuthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006, 21:598-604. 10.1093/ndt/gfi181, 16221708.
13. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005, 16:46-51.
14. Wu M, Wahl PR, Le HM, Wackerle-Men Y, Wuthrich RP, Serra AL. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007, 30:253-259. 10.1159/000104818, 17596700.
15. Wu M, Arcaro A, Varga Z, Vogetseder A, Le HM, Wuthrich RP, et al. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol 2009, 297:F1597-F1605. 10.1152/ajprenal.00430.2009, 19776171.
16. Bovenschen HJ, Janssen MJ, van Oijen MG, Laheij RJ, van Rossum LG, Jansen JB. Evaluation of a gastrointestinal symptoms questionnaire. Dig Dis Sci 2006, 51:1509-1515. 10.1007/s10620-006-9120-6, 16927133.
17. 2011, Ref Type: Internet Communication., http://www.euroqol.org
18. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009, 76:149-168. 10.1038/ki.2009.128, 2812475, 19455193.
19. Temmerman F, Missiaen L, Bammens B, Laleman W, Cassiman D, Verslype C, et al. Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther 2011, 34:702-713. 10.1111/j.1365-2036.2011.04783.x, 21790682.
20. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010, 363:820-829. 10.1056/NEJMoa0907419, 20581391.
21. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010, 363:830-840. 10.1056/NEJMoa1003491, 20581392.